8-K: ImmunityBio 2026 Annual Meeting Results

ImmunityBio, Inc. successfully held its 2026 Annual Meeting of Stockholders, confirming the re-election of all nine director nominees and the ratification of its independent auditor.

Summary

• The 2026 Annual Meeting of Stockholders was held on June 9, 2026.
• A quorum was achieved with 885,167,059 shares represented, representing approximately 85% of the 1,047,345,861 outstanding shares.
• All nine director nominees were re-elected to serve one-year terms expiring in 2027.
• Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine corporate governance filing that confirms the status quo without introducing new financial or strategic catalysts.

Positives

• High voter turnout with 85% of outstanding shares represented at the meeting.
• Strong shareholder support for the incumbent board of directors.
• Successful ratification of the independent auditor, ensuring continuity in financial oversight.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing exclusively on the results of the annual shareholder meeting.

Industry Context

StockSavvy.ai notes that the high participation rate and unanimous re-election of the board suggest stable corporate governance and strong alignment between management and the shareholder base, which is typical for established biotech firms seeking to maintain strategic continuity.

Comparison to Industry Standards

• The 85% quorum rate is robust compared to typical small-to-mid-cap biotech annual meetings, which often struggle with retail shareholder engagement.
• The re-election of the board aligns with standard industry practices for maintaining leadership stability during critical clinical development phases.

Corporate Governance

Stakeholder Impact

• Shareholders maintain continuity in board oversight.
• The company continues its established governance structure.

Next Steps

• Directors will serve their one-year terms until the 2027 annual meeting.

Key Dates

Keywords

ImmunityBio, IBRX, Annual Meeting, Proxy Voting, Corporate Governance, Board of Directors